Латанопрост

Quick links

Choose a section

Quick links to important sections

Advertisements

Латанопрост

Advertisements
Advertisements

Treatment option: Hypertension, Glaucoma

Advertisements

Overview of Латанопрост

Property Description
Active ingredient Latanoprost
Form Ophthalmic solution (Eye drops)
Pharmacological class Prostaglandin F2alpha analog
Common purpose Reduction of elevated intraocular pressure (IOP)
Origin Synthetic (Pro-drug, Isopropyl ester)

Defining Латанопрост: Classification and General Purpose

Латанопрост is fundamentally an advanced antiglaucoma preparation and a powerful ocular hypotensive agent designed for topical use. The primary therapeutic goal of this medication, which is clinically recognized for its effectiveness in pressure management, is the sustainable reduction of elevated intraocular pressure (IOP). Pharmacologically, Латанопрост is classified as a Prostaglandin F2alpha analog, belonging to the group of synthetic compounds known as prostanoids. Latanoprost lowers elevated IOP in patients, providing pressure control essential for managing ocular conditions associated with chronic high pressure, such as chronic open-angle glaucoma.

Composition, Form, and Origin: The Latanoprost Entity

The core of the medicine is the single active ingredient, Latanoprost (C25H38O5). The substance is synthetic and is specifically formulated as an isopropyl ester, which functions as a pro-drug that is activated upon application. The pro-drug design facilitates enhanced corneal penetration before activation. Латанопрост is supplied as a sterile ophthalmic solution (eye drops), ensuring its suitability for topical ophthalmic administration as a single active ingredient product. This form provides localized delivery, minimizing systemic exposure.

Unique Action: How Latanoprost Differs

Latanoprost distinguishes itself by primarily working to enhance the eye’s natural fluid drainage, facilitating efficient removal of aqueous humor. Unlike other antiglaucoma medications that primarily reduce fluid production, Latanoprost's key action is to increase the uveoscleral outflow, the secondary drainage pathway. This unique mechanism of enhancing drainage makes the compound an effective and long-acting agent for sustained pressure reduction.

Regulatory References

  1. NIH DailyMed Latanoprost Label
  2. MedlinePlus Drug Information on Latanoprost
Advertisements

What side effects are possible with Латанопрост?

Official Adverse Reactions and Safety Profile

The safety profile for Latanoprost (Латанопрост) is documented through regulatory classification systems, primarily detailing effects on the eye and surrounding structures, though systemic reactions are also noted. All information regarding frequency and severity is derived from governmental regulatory sources.

Frequency Classification of Adverse Effects

Frequency Category Representative Adverse Reactions
Very Common (ge 1/10) Iris hyperpigmentation; Conjunctival hyperaemia (eye redness); Ocular irritation (stinging, burning, foreign body sensation); Eyelash changes.
Common (ge 1/100 to <1/10) Blepharitis; Eye pain; Vision blurred; Punctate keratitis (often asymptomatic); Headache.
Uncommon (ge 1/1,000 to <1/100) Iritis/Uveitis (intraocular inflammation); Macular oedema; Eyelid skin darkening; Asthma; Angina; Nausea.

Pigmentation and Eyelash Patterns

Iris hyperpigmentation (increased brown color) is a very common, dose-exposure-related effect that is generally expected to progress while the medicine is used and is considered likely to be permanent upon discontinuation. Conversely, changes to eyelashes and eyelid skin darkening are documented as being reversible in some patients after treatment is stopped.

Serious and Population-Specific Safety Notes

The regulatory profile lists several serious adverse reactions, including the risk of Macular Oedema, which has been reported mainly in patients with specific ocular risk factors. Cases of Intraocular Inflammation (Iritis/Uveitis) and Herpetic Keratitis are also documented. For the pediatric population, data for infants under one year old are noted as very limited. Furthermore, the risk associated with use during pregnancy is officially unknown.

Advertisements

Overdose and Emergency Response

The official regulatory documentation for Latanoprost ophthalmic solution details the specific manifestations and required emergency actions associated with overdose. The profile primarily differentiates between effects resulting from the topical over-application of the eye drops and the potential for systemic exposure following accidental ingestion.

Documented Manifestations and Local Response

If excessive amounts of the solution are applied directly to the eye, the documented clinical signs are typically limited to local effects, which include conjunctival hyperemia (redness of the eye) and eye irritation. Should ocular over-application occur, the officially described procedural step is to rinse the affected eye with warm water.

When to Seek Immediate Medical Help

The circumstance that triggers the highest level of regulatory concern and mandate for immediate action is accidental ingestion (swallowing) of the eye drops. In this event, professional medical assistance must be sought urgently. Regulatory statements require contacting a healthcare professional, a hospital emergency department, or a regional Poison Control Centre immediately for guidance and potential monitoring.

Management Protocol

The management strategy for an overdose situation is defined as symptomatic and supportive treatment. This is the standard course of action, as the official prescribing information does not document or specify the availability of a particular antidote for Latanoprost.

Advertisements

Therapeutic Uses of Латанопрост

Protection Against Irreversible Vision Damage

Латанопрост is a prescription eye drop generally used for the long-term management of open-angle glaucoma and ocular hypertension (high pressure inside the eye). This medication is applied in conditions where symptoms create noticeable physiological strain linked to organ-specific functional stress. The medication is used to address this risk, assisting in the long-term goal of preserving the visual field and acuity. The medication assists with managing high eye pressure (IOP).

“This treatment assists in maintaining stable pressure, which supports the patient’s long-term visual health.”


Sustained Management of High Eye Pressure (IOP)

This medication is part of a therapeutic domain focused on managing a chronic, asymptomatic risk factor, rather than providing relief for acute symptoms. Applied in scenarios where additional management of discomfort is required, the treatment supports the management of this chronic condition and helps maintain functional stability for routine activities. It is relevant when supportive symptom management is appropriate to address functional strain. This medication is commonly used across conditions characterized by periods of heightened symptoms, such as the management of elevated IOP related to open-angle glaucoma and ocular hypertension.

Quick Fact: Relief for conditions involving increased physiological stress

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility to Use Latanoprost

Official regulatory documents define specific patient populations for whom Latanoprost ophthalmic solution is permitted, restricted, or contraindicated. Eligibility is strictly governed by pre-existing conditions and physiological status, not therapeutic efficacy.

Contraindicated Populations

Use of Latanoprost is contraindicated in patients with a known hypersensitivity or allergy to the active substance, Latanoprost, or to any excipient, such as benzalkonium chloride.


Age- and Condition-Based Restrictions

Population Group Regulatory Status Key Constraint
Adults & Older Adults Approved Generally permitted for treating elevated intraocular pressure (IOP).
Pediatric Patients Approved/Limited Approved for children and adolescents; data is limited for infants under 1 year of age and preterm infants.
Pregnancy Not Recommended Use is not recommended during pregnancy.
Lactation Not Recommended Not recommended for breastfeeding women, as the drug may pass into breast milk.
Ocular Inflammation Use with Caution Generally not recommended for patients with active intraocular inflammation (e.g., iritis or uveitis).
Aphakic/Pseudophakic Use with Caution Caution advised for patients without a lens (aphakic) or those with a torn posterior lens capsule, due to risk factors for macular edema.

These constraints establish the formal regulatory boundaries, defining who may use the medicine and the specific circumstances under which use is limited or restricted by official health authorities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Latanoprost ophthalmic solution centers on localized drug interactions and administration constraints, as the drug's topical use results in negligible systemic exposure. Consequently, regulatory documents do not cite clinically relevant systemic drug interactions involving CYP enzymes, drug transporters, food, alcohol, or herbal products.

Prohibited Combinations and Paradoxical Effects

Co-administration with specific eye drop categories is formally restricted due to documented interaction risks:

  • Other Prostaglandin Analogs: The concurrent use of Latanoprost with other prostaglandin analogs (e.g., Travoprost, Bimatoprost) is restricted because regulatory data indicates it can lead to a paradoxical elevation of Intraocular Pressure (IOP).
  • Thiomersal-Containing Ophthalmic Products: Combination with solutions containing the preservative thiomersal is restricted due to a documented risk of chemical precipitation.

Additive Effects and Administration Rules

Latanoprost is documented to produce an additive reduction in IOP when co-administered with other classes of ocular hypotensive agents, including ophthalmic beta-blockers, adrenergic agonists, and carbonic anhydrase inhibitors.

Timing-Based Separation Requirements

The regulatory profile mandates specific timing requirements for the concurrent use of other products:

  • Other Topical Eye Medications: All other topical ophthalmic products must be administered at least five (5) minutes apart from Latanoprost to prevent washout.
  • Soft Contact Lenses: Contact lenses must be removed before administration due to the Latanoprost preservative, Benzalkonium Chloride, and may be reinserted fifteen (15) minutes following application.
Advertisements

Mechanism of Action

️ How Латанопрост Works

The mechanism of action is focused on initiating a targeted biological cascade that reduces resistance to fluid flow within the eye, resulting in the physiological alteration of intraocular pressure.

Activation of Prostanoid FP Receptors

The action begins with the drug's active molecule, latanoprost acid, functioning as a highly selective agonist of the Prostanoid FP receptor found on the ciliary body. This selective molecular interaction is the essential trigger that initiates the entire sequence of downstream events that modulate eye fluid dynamics.

Remodeling of Tissue Structure and Permeability

The receptor activation causes the upregulation of Matrix Metalloproteinases (MMPs), which are enzymes that modify the Extracellular Matrix (ECM) surrounding the ciliary muscle fibers. This enzymatic tissue remodeling physically widens the interstitial spaces, thereby reducing resistance and increasing the permeability of the drainage tissue.

Enhancement of Uveoscleral Outflow

The primary physiological consequence of the reduced tissue resistance is the enhanced flow of aqueous humor through the uveoscleral outflow pathway. This augmented fluid clearance is a direct functional consequence of the altered fluid dynamics, expressed as a reduction in Intraocular Pressure (IOP).

Advertisements

Dosage and Administration Information

Administration Scope: Standard Guidelines

Latanoprost is supplied as a 0.005% sterile ophthalmic solution and is administered via the topical ophthalmic route. The standard regimen for adults, including older adults, and authorized pediatric patients is one drop in the affected eye(s). The dosage must not exceed once daily, as more frequent administration may lessen the pressure-lowering effect or cause paradoxical elevations in intraocular pressure. Optimal effect is typically obtained when the drop is instilled in the evening.

Property Value
Route of Administration Topical Ophthalmic
Dosing Schedule One drop in the affected eye(s)
Maximum Frequency Once daily (must not be exceeded)
Timing Constraint Administered in the evening

Procedural and Time-Separation Rules

If a dose is missed, the standard instruction is to skip the forgotten dose and continue with the next scheduled dose as normal, without doubling the application. For patients wearing contact lenses, the lenses must be removed prior to application and may be reinserted 15 minutes after administration. If Latanoprost is used concurrently with other topical ophthalmic drugs, each medication must be administered at least five minutes apart to prevent dilution or potential precipitation. The therapy is typically employed as continuous, long-term management.

Connection to the overall use protocol These instructions establish Latanoprost as a continuous, once-daily, topical ophthalmic treatment. The explicit dosage and frequency rules standardize the application, maintaining the therapeutic effectiveness, while the time-separation protocols ensure proper use in conjunction with contact lenses or other topical preparations.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Латанопрост is a prostaglandin F2 alpha analogue used to manage elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Phase 3 Clinical Trials

Research has explored whether clinical outcomes are affected in patients. These studies indicate that the drug was evaluated for a reduction in key symptoms, with initial studies showing a reduction in IOP that was often maintained long-term. Three of four large, randomized, double-blind trials suggested that once-daily latanoprost was associated with a greater IOP reduction compared to twice-daily timolol.

  • Trial protocols for this research specified the administration schedule.
  • The IOP-lowering effect typically begins 3-4 hours post-administration, reaches its maximum at 8-12 hours, and is sustained for at least 24 hours.

Study Focus and Findings

Studies suggest the drug's activity was examined for whether this correlated with a reduction of inflammation. The combination of active ingredients was evaluated for its effect on specific patient-reported outcomes (PROs), which includes measures of eye comfort.

Population Data

Data suggests that the drug was studied in most adult populations, but participants with certain conditions, such as kidney impairment or active intraocular inflammation, were excluded from the initial trials. The drug is generally well-tolerated in clinical studies.

  • Studies recorded common adverse events, including temporary conjunctival hyperemia (redness) and irritation. Less common but notable effects included increased length, thickness, and pigmentation of the eyelashes, and potential changes to the iris color (a permanent increase in brown pigment).
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Латанопрост (FAQ)

Q: Латанопрост – это одно и то же, что и другие 'просты'?

Latanoprost belongs to a class of medications called prostaglandin F2α analogs. While they share a similar mechanism—enhancing fluid drainage—they are not identical compounds. Official documents state that Latanoprost should not be used concurrently with other prostaglandin analogs, indicating that they are distinct but related substances in the same therapeutic category.


Q: Насколько быстро начинает действовать Латанопрост?

According to official product information, the pressure-lowering effect typically begins approximately 3 to 4 hours after the drop is administered. The maximum reduction in intraocular pressure is usually reached 8 to 12 hours after application.


Q: Как долго длится эффект снижения давления после закапывания?

Studies and official information indicate that the pressure reduction achieved from a single, daily dose is sustained for at least 24 hours. This long duration of action is consistent with the requirement for once-daily dosing.


Q: Что делать, если пропустил дозу Латанопроста?

In the event of a missed dose, official guidance states that the application should not be doubled. Treatment should continue with the next scheduled dose at the usual time.


Q: Есть ли привыкание к Латанопросту со временем?

Clinical studies, including those that followed patients for extended periods, have generally not shown evidence of tachyphylaxis (a decrease in the drug's effectiveness over time). Clinical data suggests the pressure-lowering effect is stable and maintained over long-term treatment periods.


Q: Как долго можно применять Латанопрост?

Latanoprost is commonly used as a continuous, long-term management therapy for elevated intraocular pressure. Clinical data supports its use for extended durations, and the drug is often utilized for as long as pressure control is required.


Q: Латанопрост и алкоголь — есть ли риск?

The official regulatory documents on drug interactions do not cite any known clinical interactions between Latanoprost and alcohol. Because Latanoprost is administered topically to the eye, systemic exposure is generally low.


Q: Что будет, если случайно закапать больше одной капли?

Regulatory labeling indicates that the dosage must not exceed one application per day, as applying the drops more frequently can potentially lessen the pressure-lowering effect. Overdose may lead to temporary, mild symptoms like eye redness (conjunctival hyperaemia), but serious systemic effects are not expected.


Q: Может ли Латанопрост вызвать сухость глаз?

Yes, dry eye is listed in official product documentation as an uncommon side effect. If symptoms of dry eye develop or persist, official information advises seeking medical guidance.


Q: Подходит ли Латанопрост для лечения детской глаукомы?

The medication is approved for use in children and adolescents, typically utilizing the same once-daily dose as adults. However, regulatory data is noted as being very limited for treating infants under one year of age.


Q: Влияет ли Латанопрост на артериальное давление?

Since Latanoprost is primarily a topical eye treatment, significant systemic effects are rare. Uncommon side effects listed in official documents include cardiac issues such as angina (chest pain) and palpitations (pounding heartbeat). These events are reported in the safety profile.


Q: Можно ли использовать Латанопрост при конъюнктивите?

Official information advises caution or avoidance when there is active intraocular inflammation, such as iritis or uveitis. Conjunctivitis (inflammation of the outer eye surface) is not specifically listed as a contraindication. Official guidance states that any change in eye condition, including inflammation, warrants consulting a healthcare professional.


Q: Правда ли, что Латанопрост может изменить форму зрачка?

Direct changes to the shape of the pupil are not documented in the official regulatory summary. However, the safety profile lists the rare occurrence of an iris cyst (a structural change in that part of the eye).


Q: Каковы стандартные ожидания от Латанопроста?

The primary expected outcome, as confirmed by clinical trials, is a sustained reduction in elevated intraocular pressure (IOP). The treatment is used to maintain eye pressure within a range that supports eye health.


Q: Что делать, если я забыл Латанопрост и он был вне холодильника несколько часов?

Unopened bottles must be stored under refrigeration. Once opened, the medicine is generally safe to store at a controlled room temperature (up to 25 C) but must be discarded after a specific period (typically four to six weeks). Regulatory guidelines indicate that the medicine should not be frozen.


Q: Если у меня только один глаз нуждается в лечении, нужно ли капать в оба?

Regulatory instructions state that the medicine should be administered to the affected eye(s). The determination of whether to treat one or both eyes is based on the specific medical assessment by a healthcare professional.


Q: Что делать, если капли жгут или щиплют при закапывании?

Ocular irritation (which includes stinging, burning, or a foreign body sensation) is listed as a very common side effect of this medication. If irritation becomes severe or persistent, the official safety documentation recommends seeking medical guidance.


Q: Влияет ли Латанопрост на вождение автомобиля?

The official product information notes that, like other ophthalmic preparations, Latanoprost may cause temporary blurring of vision upon application. The presence of temporary blurring means that driving or operating machinery should be avoided until visual acuity is fully restored.


Q: Почему важно использовать Латанопрост регулярно и в одно и то же время?

Official dosing instructions specify that the drug should be administered once daily, preferably in the evening. This routine is critical because it has been shown in studies to be the best way to achieve the optimal and consistent pressure-lowering effect over a 24-hour period.


Q: Есть ли какие-либо ограничения по еде или напиткам при приеме Латанопроста?

Regulatory documents state that no known interactions between Latanoprost and specific foods or non-alcoholic beverages have been identified. The treatment is localized to the eye, minimizing the risk of systemic food interactions.


Q: Что делать, если Латанопрост попал на кожу?

The official safety profile notes that the drug can cause the darkening of the eyelid skin, an effect that may be reversible once use is stopped. This finding suggests that minimizing contact with the surrounding skin is important.


Q: Может ли Латанопрост взаимодействовать с БАДами или витаминами?

Official regulatory documents do not cite any known clinical interactions between Latanoprost and herbal products or systemic vitamins/supplements. The drug's mechanism is highly localized.


Q: Почему говорят, что Латанопрост является лекарством 'первой линии'?

Latanoprost has been extensively evaluated in clinical trials and is proven to be effective at reducing intraocular pressure. Due to its demonstrated efficacy and favorable long-acting profile, it is often referenced in clinical guidelines as one of the preferred initial treatment options.


Q: Помогает ли Латанопрост при других заболеваниях глаз, кроме глаукомы?

The medicine is officially indicated only for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is not approved for treating other eye conditions.


Q: Правда ли, что Латанопрост нельзя использовать при воспалении?

Official regulatory warnings advise against its use in the presence of active intraocular inflammation, such as iritis or uveitis. Caution is also advised in patients with a history of certain viral eye infections.


Q: Может ли Латанопрост ухудшить течение катаракты?

While there is no information indicating Latanoprost worsens the underlying condition of cataracts, the regulatory profile advises caution for use in patients who have undergone cataract surgery, particularly those with risk factors for macular oedema (swelling at the back of the eye).


Q: Латанопрост — это дженерик или оригинальный препарат?

Latanoprost is the name of the active chemical ingredient. It has been available under a specific brand name (the original formulation) and is also widely available in many countries as a generic version, depending on the specific product formulation.

Advertisements

How should Латанопрост be stored and disposed of?

How to Store and Dispose of Latanoprost

Official regulatory labeling dictates specific storage and disposal requirements for latanoprost ophthalmic solution to maintain its stability and effectiveness.

Required Storage Conditions

Container Status Required Temperature Shelf-Life Constraint
Unopened Bottle Refrigerated (2 C to 8 C) Store in original carton to protect from light.
Opened Bottle Controlled Room Temperature (up to 25 C) Must be discarded after six weeks (42 days).

Latanoprost must not be frozen under any circumstances. The bottle must be kept tightly closed when not in use. For child safety, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

All unused or expired latanoprost solution and waste material must be disposed of in accordance with local requirements for pharmaceutical products. The medicine should generally not be discarded via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Латанопрост found in:

A-Z Index: